Nevro ($NVRO) revealed that Boston Scientific ($BSX) is challenging its patent for "selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods," and promised to vigorously defend its intellectual property in the matter. Boston Scientific's move comes on the heels of FDA approval of Nevro's Senza System, which fights chronic pain in the back and legs without causing a tingling sensation known as paresthesia by delivering high-frequency stimulation at 10 kilohertz and low amplitudes. The FDA approved the device with superiority labeling after a clinical trial found Senza patients had better outcomes than those on traditional stimulators. Boston Scientific makes the Precision Plus and Precision Spectra spinal cord stimulation systems. Release | More about the patent